Latest News

Find updates from Cogstate, leaders in the measurement of cognition.

ERT Announced Partnership with Cogstate to Expand its eCOA Solution for Higher Fidelity CNS Assessments

ERT Announced Partnership with Cogstate to Expand its eCOA Solution for Higher Fidelity CNS Assessments

ERT, the global leader in clinical endpoint data collection, today announced a preferred partnership with Cogstate to expand its industry-leading electronic Clinical Outcome Assessment (eCOA) solution with digital cognitive endpoints from Cogstate to support the development […]

July 22, 2020
Cogstate Receives Digital Biomarker Award from ADDF to Develop Mobile App for Early Detection of Memory Impairment

Cogstate Receives Digital Biomarker Award from ADDF to Develop Mobile App for Early Detection of Memory Impairment

Cogstate today announced an award from the Alzheimer’s Drug Discovery Foundation’s (ADDF) Diagnostics Accelerator (DxA) initiative, which is a partnership of funders seeking to develop novel biomarkers for the early detection of Alzheimer’s disease and related dementias. The up to $1.3 million award to Cogstate will be focused on the development of a technology-based approach for early detection of memory impairment and decline.

April 29, 2020
Eisai launches Cogstate technology in Japan as digital brain performance tool

Eisai launches Cogstate technology in Japan as digital brain performance tool

Eisai Co., Ltd (Tokyo) today announced the launch of “NouKNOW”, a digital tool for self-assessment of brain health based upon technology created by Cogstate. The Japanese product launch will occur on 31 March 2020 and will initially target municipalities providing health services to local residents and corporations providing health checks for employees.

March 23, 2020
Cogstate Expands Executive Team, Appointing Ken Billard as Chief Commercial Officer

Cogstate Expands Executive Team, Appointing Ken Billard as Chief Commercial Officer

Cogstate announced today that Ken Billard has joined the company in the role of Chief Commercial Officer. Ken brings proven expertise in sales leadership and strategic partnering to Cogstate, where he will oversee the global sales organization to develop and execute strategies focused on expanding the adoption of Cogstate solutions in pharmaceutical clinical trials.

November 19, 2019
Cogstate to Present at the NORD Rare Diseases and Orphan Products Breakthrough Summit

Cogstate to Present at the NORD Rare Diseases and Orphan Products Breakthrough Summit

Cogstate today announced a presentation entitled, “Methodology for Development of Indication-Specific Outcome Measures in Rare Disease Trials: An Innovative Research Approach” will be delivered at the National Organization for Rare Diseases (NORD) Rare Disease Summit in Washington, D.C.

October 11, 2018
Cogstate announces European approval for Healthcare offering

Cogstate announces European approval for Healthcare offering

Cogstate, today announced that its Healthcare Division has received CE Mark approval for its Cognigram™ digital cognitive assessment system.

June 4, 2018
Cogstate Scientists Contribute to New Research Framework to Redefine Alzheimer’s Disease

Cogstate Scientists Contribute to New Research Framework to Redefine Alzheimer’s Disease

A new research framework for understanding Alzheimer’s disease has been developed and released by the Alzheimer’s Association (AA) and the National Institute on Aging (NIA).

April 17, 2018
Cogstate Establishes Rare Disease and Pediatric Center of Excellence

Cogstate Establishes Rare Disease and Pediatric Center of Excellence

Cogstate today announced the establishment of a Rare Disease and Pediatric Center of Excellence to lead all activities related to the selection and administration of cognitive and behavioral outcome measures in rare disease and pediatric clinical trials.

April 5, 2018
Eric Siemers, M.D., Named Distinguished Medical Adviser at Cogstate

Eric Siemers, M.D., Named Distinguished Medical Adviser at Cogstate

Cogstate today announced the appointment of Eric Siemers, M.D., as Distinguished Medical Adviser. Dr. Siemers will provide expert advice for Cogstate’s pharmaceutical customers with regard to the design of clinical trials of neurodegenerative diseases.

February 27, 2018
International publications validate Cogstate technology’s clinical value in detecting  Postoperative Cognitive Dysfunction (POCD)

International publications validate Cogstate technology’s clinical value in detecting Postoperative Cognitive Dysfunction (POCD)

From the Interdisciplinary Conference on Orthopedic Value Based Care sponsored by the American College of Perioperative Medicine, Cogstate announced that the Cogstate Brief Battery™ has now been shown to be useful for guiding decision making about cognitive outcomes in older adults awaiting or undergoing surgery.

February 12, 2018
Cogstate Strengthens Global Clinical Science Expertise with the Appointment of Senior Vice President, Dr. Chris Edgar

Cogstate Strengthens Global Clinical Science Expertise with the Appointment of Senior Vice President, Dr. Chris Edgar

Cogstate today announced the addition of Dr. Chris Edgar, Senior Vice President, Clinical Science to its global scientific leadership team. Dr. Edgar joins the Cogstate team in Europe as an experienced leader in cognitive assessment and clinical endpoint strategy.

February 9, 2018
Global Alzheimer’s Platform Foundation Selects Cogstate for Industry-First Rater Certification Program

Global Alzheimer’s Platform Foundation Selects Cogstate for Industry-First Rater Certification Program

Cogstate today announced it has been chosen by the Global Alzheimer’s Platform (GAP) Foundation to support GAP’s rater certification program (RCP) that will significantly increase the speed and quality of Alzheimer’s clinical trials.

January 24, 2018

How can we help you optimize the measurement of brain health?

Please fill out the form to get in touch